Biotech Pioneer · AI Founder · 11 Patents

Gauri
Naik

Co-Founder & CEO — OptraHEALTH

She built a chatbot that answers 500,000 questions about hereditary cancer — on Amazon Alexa, in 2018. Now she's orchestrating AI across the most complex workflows in medicine.

AI & NLP Genomics Revenue Cycle Digital Pathology HealthGPT Silicon Valley
Dr. Gauri Naik, Co-Founder and CEO of OptraHEALTH
Dr. Gauri Naik · OptraHEALTH
11 U.S. Patents
20+ Years in Health AI
500K+ Cancer Q&As Answered
65M Medical Ontologies in HealthGPT
72 OptraHEALTH Employees
The Story

The Scientist Who Didn't Stop at Science

When most biotech companies were still printing PowerPoint slides about genomic data's potential, Gauri Naik was filing patents. Eleven of them. The one granted in August 2020 — U.S. Patent 10,754,882 — covers AI chatbot technology that automates clinical workflows for genetic test results. It would later become the center of a lawsuit against Invitae, one of the largest genetic testing companies in the country, after they paid $50 million to acquire a competing chatbot called "Gia." The case settled. Invitae licensed the patent.

That's the kind of quiet leverage that doesn't make headlines — until it does.

Gauri holds a Ph.D. in a life sciences discipline, and she started building companies before "AI healthtech" was a pitch deck category. In 2003, she co-founded BioImagene Inc. in Silicon Valley — a digital pathology company working on imaging technology for pathology slides when pathology labs were still entirely analog. Roche Diagnostics acquired it. She stayed long enough to see the exit through, then started again.

"The convergence of artificial intelligence, conversational technologies like Alexa, and an ever-increasing availability of data is having a transformative effect on how research and clinical results are delivered and communicated."

- Gauri Naik, 2018

Optra Systems came next in 2010 — an engineering services company serving medical device and lab instrumentation firms. By 2014 she was also an investor and board member at OptraSCAN, a digital pathology platform bridging California and Pune, India. The pattern: build something real, get it acquired or established, move into the adjacent problem.

In 2017, she co-founded OptraHEALTH. The thesis was specific: genetics and genomics generate an enormous amount of information that patients, providers, and payers all need to act on — and almost none of it flows well. Genetic counselors are scarce. Insurance authorizations are slow. Clinical documentation is a burden. None of this requires a breakthrough in biology. It requires intelligent software, built by someone who understands both the science and the enterprise.

Gauri understood both.

"HealthGPT was trained on 65 million ontologies and 2 million curated healthcare Q&A pairs — before the ChatGPT gold rush."

OptraHEALTH, March 2023
2003 First company co-founded
(BioImagene → Roche)
2018 Alexa genomics platform
launched at ASHG
2022 Patent suit filed
vs. Invitae
2023 HealthGPT launched
with private cloud deploy
What OptraHEALTH Builds

Four Platforms. One Problem.

Healthcare produces information that doesn't move. Genetic results sit in reports no patient can read. Prior authorizations age in queues. Clinical codes get entered wrong. OptraHEALTH's platform suite is built around the thesis that AI should handle the movement — so people can handle the decisions.

Flagship Platform

HealthFAX

Unified clinical and revenue intelligence. NLP + machine learning + knowledge graphs automating ICD/CPT coding, prior authorization, eligibility verification, and patient engagement — across voice, web, mobile, and WhatsApp.

Genomics AI

GeneFAX

AI-guided genetic test recommendations, e-counseling, and an intelligent chatbot that can answer 500,000+ questions about hereditary cancer. Launched as an Amazon Alexa skill in 2018. Available for Cortana, Google Home, and mobile.

Patient Companion

AiCounsyl

Personal health companion for patients navigating cardiac and lab reports. Translates clinical language into plain language — the difference between a report and an understanding.

LLM Engine

HealthGPT

Launched March 2023. A transformer-based neural engine trained on 65 million medical ontologies and 2 million curated Q&A pairs. Private cloud deployment. HIPAA-compatible. Follows ACOG, NCCN, ACMG, and AHA guidelines.

Added May 2025

Clinical Intelligence Engine

The newest addition to HealthFAX — real-time clinical decision support layered onto the existing revenue cycle and patient engagement platform. Announced at HIMSS 2026.

Services

AI Consulting

Custom LLMs, generative AI implementation, and orchestration via "AI Delivery Pods" — a team model for deploying and integrating AI across complex health system environments.

Career Arc

Twenty Years, One Direction

2003
Co-founded BioImagene Inc. — Silicon Valley digital pathology. Focused on imaging technology for histopathology slides before the field had a name.
2009
BioImagene acquired by Roche Diagnostics. Exit from a company built from scratch in a pre-cloud, pre-AI era of medical imaging.
2010
Co-founded Optra Systems Inc. Engineering support for medical device and lab instrumentation companies — design through regulatory compliance.
2014
Became investor and board member at OptraSCAN — digital pathology with offices in San Jose and Pune, India. Began building the trans-Pacific operating model.
2016
Presented iPhronesis platform — big data analytics for personalized and precision medicine — at international conference in Phoenix. Published in Journal of Pharmacogenomics & Pharmacoproteomics.
2017
Co-founded OptraHEALTH — the AI clinical and revenue platform combining genomics intelligence with enterprise health IT.
2018
GeneFAX launched at ASHG Conference in San Diego. Integrated Amazon Alexa to answer 500,000+ questions about hereditary cancer. One of the first genomics platforms deployable as a voice skill.
2020
US Patent 10,754,882 granted — AI chatbot for clinical genomic workflows. Partnered with Myriad Genetics to launch "Gene" chatbot, reaching 1 million annual quiz users.
2022–2023
Filed patent suit against Invitae. Settled with licensing agreement. Launched HealthGPT. Expanded to Thailand via Bumrungrad Hospital — first major APAC deployment.
2024–2026
ENGAGE study with Johns Hopkins published in Springer Nature. Clinical Intelligence Engine added to HealthFAX. HIMSS 2026 presence. Continued global expansion.
Intellectual Property

The Patents That Proved the Point

Eleven U.S. patents is an unusual number for a startup CEO — typically, you find counts like that on researchers who have never shipped a product. Gauri has done both. The patents cover AI chatbot technology, clinical workflow automation, and genomics informatics. They are not defensive filings collecting dust.

The most consequential: US Patent 10,754,882, granted August 2020, covering AI chatbot technology that automates clinical workflows for delivering genetic test results. When Invitae — by then one of the largest genetic testing companies in the US — deployed its "Gia" chatbot (purchased from Clear Genetics for $50 million in 2019), OptraHEALTH filed suit in the Northern District of California.

The case settled in 2022-2023. The terms: a licensing agreement that allowed both parties to continue operating their products independently. For a company of OptraHEALTH's size filing against Invitae's scale, the outcome was a validation of the original IP — and of the years spent filing before building.

US PATENT 10,754,882

AI Chatbot for Genetic Workflow Automation

Granted August 2020. Covers AI chatbot technology automating clinical workflows for delivering genetic test results. Subject of 2022 litigation vs. Invitae; settled via licensing agreement.

11 PATENTS TOTAL

NLP, Clinical AI & Genomics Informatics

Across conversational AI, natural language processing, clinical workflow automation, and genomics informatics. Filed progressively from 2017 onward as OptraHEALTH's platform expanded.

In Her Words

What She Actually Says

"AI in healthcare is no longer about whether organizations will adopt it — that part is already happening. The real challenge now is operational orchestration."

- Gauri Naik, HIMSS 2026

"The success of the ENGAGE study marks a pivotal moment in our commitment to redefining patient education."

- January 2024, on Johns Hopkins Hospital study publication

"OptraHEALTH aims to make HealthFAX widely accessible to all families in need of more information about genetic testing for autism spectrum and other genetic disorders."

- September 2022, on Bionano Laboratories partnership

"We are super-excited to partner with Bumrungrad Hospital. With growing traction in North America and Europe, we are happy to make our products available for APAC customers."

- May 2023, on Thailand expansion
Notable Partnerships & Milestones

Where HealthFAX Actually Runs

Date Partner / Event What It Means
Jul 2020 Myriad Genetics Launched "Gene" chatbot for hereditary cancer; reached 1 million annual quiz users
Nov 2019 InformedDNA Remote genetic counseling expansion via GeneFAX CounselorConnect
Sep 2022 Bionano Laboratories AI genetic counseling for autism spectrum and rare disorders via WhatsApp + HealthFAX
Jan 2024 Johns Hopkins Hospital ENGAGE study — 64 patients, breast and prostate cancer — published in Journal of Cancer Survivorship (Springer Nature)
May 2023 Bumrungrad Hospital, Thailand First major APAC deployment; OptraHEALTH's platform in Southeast Asia's leading international hospital
May 2025 Clinical Intelligence Engine New capability added to HealthFAX — real-time clinical decision support at the point of care
Details That Matter

Five Things Worth Knowing

🎙

GeneFAX launched as an Amazon Alexa skill at the ASHG Conference in 2018 — before most healthcare CIOs had decided whether to allow iPhones in hospitals.

🏆

Won the Woman Entrepreneur Award from the Government of India — an honor that reflects both her scientific credentials and her impact as a company builder.

📚

Editorial and advisory board member of the Journal of Applied & Translational Genomics — and still ships product at OptraHEALTH. Both at once, apparently.

🎬

Optra Ventures — the venture arm she co-founded — backs Devisha Films, an award-winning entertainment company focused on social themes. Health IT isn't the only thing on the portfolio.

🔒

HealthGPT runs on private cloud — inside a health system's firewall. Not a general-purpose LLM API. That architectural choice is a specific answer to the specific fear every hospital CIO has about AI and patient data.

🌏

The Optra operating model spans California and Pune, India — development, operations, and clinical expertise distributed across two continents, backing Indo-American entrepreneurs through Optra Ventures.

Recognition & Leadership

Beyond the Company

Gauri's scientific credibility isn't a backstory — it's load-bearing. She was selected as a young scientist for international biotechnology and microbiology research programs early in her career, a competitive credential that gave her the academic fluency to publish in peer-reviewed journals while building companies.

The ENGAGE study, conducted at Johns Hopkins Hospital between April 2021 and February 2022, enrolled 64 patients with breast and prostate cancer to test AI-assisted patient education. Its publication in Springer Nature's Journal of Cancer Survivorship in January 2024 is rare: peer-reviewed validation of a commercial product, conducted at a world-class clinical institution.

She also serves on the advisory board of the International Organization for Rare Genetic Disorders — an extension of the same commitment to making genetic information accessible that drives OptraHEALTH's commercial work.

And separately from the company: the Jiji-bhau Foundation, co-funded under the Optra umbrella, provides cancer patient support — a philanthropic commitment that runs alongside the commercial ventures, not in competition with them.

🏅 Award Woman Entrepreneur Award Government of India
📖 Editorial Board Journal of Applied & Translational Genomics

Academic & Advisory

  • → Advisory board, Intl. Org. for Rare Genetic Disorders
  • → Speaker, ASHG 2018 — GeneFAX launch
  • → Speaker, Personalized Medicine Conference 2016 (iPhronesis)
  • → HIMSS 2026 presence (Las Vegas)
  • → Published in Journal of Pharmacogenomics & Pharmacoproteomics
  • → Co-author, ENGAGE study, Springer Nature 2024
Where She Sees Things Going

The Orchestration Problem

At HIMSS 2026, Gauri put words to what OptraHEALTH has been building toward for years: the problem in healthcare AI isn't adoption — it's orchestration. Health systems have already deployed ambient documentation tools, workflow automation, predictive analytics, patient engagement platforms. Getting those systems to work together — across different vendors, workflows, and clinical teams — is where things fall apart.

OptraHEALTH's answer is HealthFAX as a unifying layer — NLP, machine learning, and knowledge graphs sitting across revenue cycle, patient engagement, clinical intelligence, and genetic counseling. Not another point solution. An integration surface.

The company is HIPAA, SOC 2 Type II, HITRUST certified, and FHIR-native. Those aren't checkboxes — in enterprise health IT, they're the price of admission.

"Many health systems already have multiple AI solutions in place — but getting those solutions to work together across systems, teams, and workflows is where things become complicated."

- Gauri Naik, HIMSS 2026

Compliance Stack

HIPAA
SOC 2 Type II
HITRUST Certified
FHIR-Native
GDPR
Private Cloud
Share Gauri Naik's Profile
Link copied to clipboard!